261 related articles for article (PubMed ID: 7667286)
1. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
2. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
3. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
4. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
5. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
6. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
7. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
8. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
9. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
[TBL] [Abstract][Full Text] [Related]
10. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
11. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
12. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
13. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
14. Evidence that binding site occupancy is necessary and sufficient for effective major histocompatibility complex (MHC) class II transport through the secretory pathway redefines the primary function of class II-associated invariant chain peptides (CLIP).
Zhong G; Castellino F; Romagnoli P; Germain RN
J Exp Med; 1996 Nov; 184(5):2061-6. PubMed ID: 8920896
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of peptide binding to DR molecules by a leupeptin-induced invariant chain fragment.
Demotz S; Danieli C; Wallny HJ; Majdic O
Mol Immunol; 1994 Aug; 31(12):885-93. PubMed ID: 8065372
[TBL] [Abstract][Full Text] [Related]
16. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II.
Sette A; Southwood S; Miller J; Appella E
J Exp Med; 1995 Feb; 181(2):677-83. PubMed ID: 7836921
[TBL] [Abstract][Full Text] [Related]
17. Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs.
Geluk A; Van Meijgaarden KE; Drijfhout JW; Ottenhoff TH
Mol Immunol; 1995 Sep; 32(13):975-81. PubMed ID: 7477003
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1.
Park SJ; Sadegh-Nasseri S; Wiley DC
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):11289-93. PubMed ID: 7479981
[TBL] [Abstract][Full Text] [Related]
19. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
[TBL] [Abstract][Full Text] [Related]
20. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
